Drug Recall Replacement for Actos Delayed

Drug Recall Replacement for Actos Delayed | Pintas & Mullins Law Firm

Takeda Pharmaceutical, the manufacturer of Alogliptin, received more discouraging news from the United States Food and Drug Administration (FDA). The FDA mandated that Takeda provide more information regarding the safety of Alogliptin, declining to approve the much-needed drug for the second time. Alogliptin was created to replace the dangerous and heavily litigated Actos. Our Illinois drug recall lawyers have extensive experience working with victims suffering from Actos side effects, obtaining our clients the compensation they deserve.

Diabetes treatment and prevention is a gargantuan facet of the pharmaceutical industry; its global health care expenditures approach $400 billion annually. Actos is a prescribed medication designed to improve and remedy the elevated blood sugar (glucose) of adults suffering from type 2 diabetes. However, despite its best efforts, in the past couple years Actos has been the source of copious litigation because of its harmful side effects. In 2011, the FDA determined that Actos directly increased the likelihood of bladder cancer by forty percent for those that have taken the drug in excess of one year. While the United States has been hesitant to force a drug recall, Actos has been banned in France. Those that have taken Actos and are suffering from bladder cancer should seek a drug recall attorney.

Because of the prevalence of diabetes and the large percentage of the pharmaceutical industry it occupies, competitors are eager to develop a drug to replace Actos, as is the drug’s original developer Takeda Pharmaceutical. Takeda made great strides with the development of Alogliptin, but again their efforts are not yet sufficient to garner the required FDA approval. 

Despite being currently marketed as Nesina in Japan, Alogliptin failed yet again to be approved by the FDA. This rejection shocked Takeda, who is anxious to remove Actos from the market. Even without the technical knowledge to ascertain Alogliptin’s faults, it isn’t too shocking that the FDA is being extremely careful in approving the improved version of Actos. Given the immense number of Americans that will be prescribed this drug, combined with the devastation caused by Actos, the FDA appears to have adopted even more heightened standards for diabetes medications.

An estimated 20 million Americans have diabetes, with an additional 40 million suffering from the pre-diabetic condition of elevated glucose. Almost more startling is its unfathomable growth rate; the number of individuals with type 2 diabetes has nearly doubled in the last four years. Further, the ADA estimated that the annual cost of disability payments to those battling diabetes to be upwards of $18 billion.

Efforts by Takeda to combat type 2 diabetes are part of a larger effort to lessen this epidemic. Among the many efforts are social programs, which are directly addressing the nutrition and health of Americans seems to be the most promising. These preventative programs have been instituted in schools across the country, mandating healthier meal alternatives. While these efforts are excellent for prevention, pharmaceuticals are still needed to help those that currently suffer with type 2 diabetes. Thus, a dilemma arises.

People suffering from type 2 diabetes must take medication to control their disease, but they are somewhat reliant on drugs that have detrimental side effects as they anxiously wait for the approval of Alogliptin. Anyone suffering from bladder cancer following taking Actos should seek advice from experienced drug recall attorneys to determine whether they have legal recourse.